Donald Fleming, MD
Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Member of the Healthcare Council
Council Member Biography
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical trials involving the treatment of hematologic and oncologic disorders. Dr. Fleming has also served as consultant for various pharmaceutical companies. (This is me - Update Profile)
Employment History
- 2008 - present
- Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
- 2002 - 2008
- Division Head of Hematology and Oncology, MEDICAL CENTER OF VINCENNES
- 1995 - 2002
- Associate Professor of Oncology / Hematology, UNIVERSITY OF LOUISVILLE
GLG NewsSM Analyses by Donald Fleming, MD(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Triple negative Breast Cancer Strategies
October 14, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com
Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as fornon...
-
Farletuzumab (F) helps the ovarian cancer patients that do well, do well?
September 25, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com
F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we...
-
Herceptin for Her2 + gastric cancer, If you can find one
September 25, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com
Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer
-
REGORAFENIB joins a crowd of TKI's for RCC
September 25, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com
RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved
Leading institutions connect with Donald Fleming, MD through GLG
GLG Study Groups with Donald Fleming, MD(?)
| Study Group Name | No. Members |
|---|---|
| Multiple Myeloma Physicians | 211 |
| Oncologists who Treat Multiple Myeloma (US) | 75 |
| Physicians who Treat Primary Pulmonary Hypertension (US) | 110 |
| Physicians who Treat CML (US) | 57 |
GLG Live Meetings with Donald Fleming, MD(?)
Donald Fleming, MD has not participated in any GLG Live Meetings.